PROTEOME SCIENCES PLC

Report Publication Announcement • May 31, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7747Z

Proteome Sciences PLC

31 May 2016

PRESS RELEASE

Proteome Sciences plc

(the "Company" or the "Group")

Publication of Annual Report

31 May, 2016:  The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company's website at www.proteomics.com, and will be posted to shareholders imminently.

ENDS

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Operating Officer	Tel: +44 (0)1932 865065
Geoff Ellis, Finance Director
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson	Tel : +44 (0)20 7220 0563
Public Relations
IKON Associates	Email: adrian@ikonassociates.com
Adrian Shaw	Tel: +44 (0)1483 271291
	Mobile +44(0)7979 900733

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant®, TMTcalibrator™) and in protein biomarker discovery, validation and assay development.

PS Biomarker Services® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSZFLFXQEFFBBX